InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,043.49
(
0.42%
)
US TECH 100
17,082.40
(
0.29%
)
Dow Jones
37,972.06
(
0.58%
)
Brent Oil
86.51
(
-0.55%
)
Bitcoin
63,533.00
(
3.67%
)
Post# of 70
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mcp4

Send PM Follow Ignore
Followers 1
Posts 103
Boards Moderated 0
Alias Born 03/08/2008

mcp4

Re: None

Thursday, 03/15/2018 1:02:32 PM

Thursday, March 15, 2018 1:02:32 PM

Post# of 70
K-10 was released earlier this month. The company anticipates higher expenses to develop KD025, KD034 and tesevatinib. None have reached Phase III in clinical trials yet.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM

ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM

Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM

Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM

Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM

Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!